Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer

H. Kennecke, L. Chen, Charles Blanke, W. Y. Cheung, K. Schaff, C. Speers

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background The survival benefit for single-agent anti-epidermal growth factor receptor (EGFR) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present study was to describe the characteristics of, and to compare survival outcomes in, two cohorts of patients treated with either singleagent panitumumab or combination therapy with cetuximab and irinotecan. Methods The study enrolled patients with KRAS wt mcrc previously treated with both irinotecan and oxaliplatin who had received either panitumumab or combination cetuximab-irinotecan before April 1, 2011, at the BC Cancer Agency (BCCA). Patients were excluded if they had received anti-egfr agents in earlier lines of therapy. Data were prospectively collected, except for performance status (PS), which was determined by chart review. Information about systemic therapy was extracted from the bcca Pharmacy Database. Results Of 178 eligible patients, 141 received panitumumab, and 37 received cetuximab-irinotecan. Compared with patients treated with cetuximab-irinotecan, panitumumab-treated patients were significantly older and more likely to have an Eastern Cooperative Oncology Group (ECOG) ps of 2 or 3 (27.7% vs. 2.7%, p = 0.001). Other baseline prognostic variables and prior and subsequent therapies were similar. Median overall survival was 7.7 months for the panitumumab group and 8.3 months for the cetuximab-irinotecan group. Multivariate analysis demonstrated that survival outcomes were similar regardless of the therapy selected (hazard ratio: 1.28; p = 0.34). An ECOG PS of 2 or 3 compared with 0 or 1 was the only significant prognostic factor in this treatment setting (hazard ratio: 3.37; p <0.01). Conclusions Single-agent panitumumab and cetuximab-irinotecan are both reasonable third-line treatment options, with similar outcomes, for patients with chemoresistant mcrc.

Original languageEnglish (US)
Pages (from-to)326-332
Number of pages7
JournalCurrent Oncology
Volume20
Issue number6
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

irinotecan
Colorectal Neoplasms
oxaliplatin
Therapeutics
Survival
panitumumab
Cetuximab

Keywords

  • Anti-EGFR
  • Cetuximab
  • Chemotherapy
  • Irinotecan
  • Mcrc
  • Multivariate analysis
  • Panitumumab
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer. / Kennecke, H.; Chen, L.; Blanke, Charles; Cheung, W. Y.; Schaff, K.; Speers, C.

In: Current Oncology, Vol. 20, No. 6, 2013, p. 326-332.

Research output: Contribution to journalArticle

@article{2defb67b359b4c988a441abcd4cb852b,
title = "Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer",
abstract = "Background The survival benefit for single-agent anti-epidermal growth factor receptor (EGFR) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present study was to describe the characteristics of, and to compare survival outcomes in, two cohorts of patients treated with either singleagent panitumumab or combination therapy with cetuximab and irinotecan. Methods The study enrolled patients with KRAS wt mcrc previously treated with both irinotecan and oxaliplatin who had received either panitumumab or combination cetuximab-irinotecan before April 1, 2011, at the BC Cancer Agency (BCCA). Patients were excluded if they had received anti-egfr agents in earlier lines of therapy. Data were prospectively collected, except for performance status (PS), which was determined by chart review. Information about systemic therapy was extracted from the bcca Pharmacy Database. Results Of 178 eligible patients, 141 received panitumumab, and 37 received cetuximab-irinotecan. Compared with patients treated with cetuximab-irinotecan, panitumumab-treated patients were significantly older and more likely to have an Eastern Cooperative Oncology Group (ECOG) ps of 2 or 3 (27.7{\%} vs. 2.7{\%}, p = 0.001). Other baseline prognostic variables and prior and subsequent therapies were similar. Median overall survival was 7.7 months for the panitumumab group and 8.3 months for the cetuximab-irinotecan group. Multivariate analysis demonstrated that survival outcomes were similar regardless of the therapy selected (hazard ratio: 1.28; p = 0.34). An ECOG PS of 2 or 3 compared with 0 or 1 was the only significant prognostic factor in this treatment setting (hazard ratio: 3.37; p <0.01). Conclusions Single-agent panitumumab and cetuximab-irinotecan are both reasonable third-line treatment options, with similar outcomes, for patients with chemoresistant mcrc.",
keywords = "Anti-EGFR, Cetuximab, Chemotherapy, Irinotecan, Mcrc, Multivariate analysis, Panitumumab, Survival",
author = "H. Kennecke and L. Chen and Charles Blanke and Cheung, {W. Y.} and K. Schaff and C. Speers",
year = "2013",
doi = "10.3747/co.20.1600",
language = "English (US)",
volume = "20",
pages = "326--332",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "6",

}

TY - JOUR

T1 - Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer

AU - Kennecke, H.

AU - Chen, L.

AU - Blanke, Charles

AU - Cheung, W. Y.

AU - Schaff, K.

AU - Speers, C.

PY - 2013

Y1 - 2013

N2 - Background The survival benefit for single-agent anti-epidermal growth factor receptor (EGFR) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present study was to describe the characteristics of, and to compare survival outcomes in, two cohorts of patients treated with either singleagent panitumumab or combination therapy with cetuximab and irinotecan. Methods The study enrolled patients with KRAS wt mcrc previously treated with both irinotecan and oxaliplatin who had received either panitumumab or combination cetuximab-irinotecan before April 1, 2011, at the BC Cancer Agency (BCCA). Patients were excluded if they had received anti-egfr agents in earlier lines of therapy. Data were prospectively collected, except for performance status (PS), which was determined by chart review. Information about systemic therapy was extracted from the bcca Pharmacy Database. Results Of 178 eligible patients, 141 received panitumumab, and 37 received cetuximab-irinotecan. Compared with patients treated with cetuximab-irinotecan, panitumumab-treated patients were significantly older and more likely to have an Eastern Cooperative Oncology Group (ECOG) ps of 2 or 3 (27.7% vs. 2.7%, p = 0.001). Other baseline prognostic variables and prior and subsequent therapies were similar. Median overall survival was 7.7 months for the panitumumab group and 8.3 months for the cetuximab-irinotecan group. Multivariate analysis demonstrated that survival outcomes were similar regardless of the therapy selected (hazard ratio: 1.28; p = 0.34). An ECOG PS of 2 or 3 compared with 0 or 1 was the only significant prognostic factor in this treatment setting (hazard ratio: 3.37; p <0.01). Conclusions Single-agent panitumumab and cetuximab-irinotecan are both reasonable third-line treatment options, with similar outcomes, for patients with chemoresistant mcrc.

AB - Background The survival benefit for single-agent anti-epidermal growth factor receptor (EGFR) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present study was to describe the characteristics of, and to compare survival outcomes in, two cohorts of patients treated with either singleagent panitumumab or combination therapy with cetuximab and irinotecan. Methods The study enrolled patients with KRAS wt mcrc previously treated with both irinotecan and oxaliplatin who had received either panitumumab or combination cetuximab-irinotecan before April 1, 2011, at the BC Cancer Agency (BCCA). Patients were excluded if they had received anti-egfr agents in earlier lines of therapy. Data were prospectively collected, except for performance status (PS), which was determined by chart review. Information about systemic therapy was extracted from the bcca Pharmacy Database. Results Of 178 eligible patients, 141 received panitumumab, and 37 received cetuximab-irinotecan. Compared with patients treated with cetuximab-irinotecan, panitumumab-treated patients were significantly older and more likely to have an Eastern Cooperative Oncology Group (ECOG) ps of 2 or 3 (27.7% vs. 2.7%, p = 0.001). Other baseline prognostic variables and prior and subsequent therapies were similar. Median overall survival was 7.7 months for the panitumumab group and 8.3 months for the cetuximab-irinotecan group. Multivariate analysis demonstrated that survival outcomes were similar regardless of the therapy selected (hazard ratio: 1.28; p = 0.34). An ECOG PS of 2 or 3 compared with 0 or 1 was the only significant prognostic factor in this treatment setting (hazard ratio: 3.37; p <0.01). Conclusions Single-agent panitumumab and cetuximab-irinotecan are both reasonable third-line treatment options, with similar outcomes, for patients with chemoresistant mcrc.

KW - Anti-EGFR

KW - Cetuximab

KW - Chemotherapy

KW - Irinotecan

KW - Mcrc

KW - Multivariate analysis

KW - Panitumumab

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84890098854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890098854&partnerID=8YFLogxK

U2 - 10.3747/co.20.1600

DO - 10.3747/co.20.1600

M3 - Article

VL - 20

SP - 326

EP - 332

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 6

ER -